Julia And Israel Waldbaum Dialysis is a medicare approved dialysis facility center in Great Neck, New York and it has 34 dialysis stations. It is located in Nassau county at 100 Community Drive, Great Neck, NY, 11021. You can reach out to the office of Julia And Israel Waldbaum Dialysis at (516) 465-8250. This dialysis clinic is managed and/or owned by Davita. Julia And Israel Waldbaum Dialysis has the following ownership type - Non-Profit. It was first certified by medicare in November, 2016. The medicare id for this facility is 332754 and it accepts patients under medicare ESRD program.
| Name | Julia And Israel Waldbaum Dialysis |
|---|---|
| Location | 100 Community Drive, Great Neck, New York |
| No. of Dialysis Stations | 34 |
| Medicare ID | 332754 |
| Managed By | Davita |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 100 Community Drive, Great Neck, New York, 11021 | |
| (516) 465-8250 | |
| Not Available |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
| NPI Number | 1043752769 |
| Organization Name | Julia And Israel Waldbaum Dialysis |
| Doing Business As | True North Dialysis Center Llc |
| Address | 100 Community Dr Great Neck, New York, 11021 |
| Phone Number | (516) 465-8250 |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 131 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 12 |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 158 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1431 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Pediatic patients getting regular hemodialysis at the center | 1 |
| Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 6 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 50 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 528 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 89 |
| Pediatric patients getting regular peritoneal dialysis at the centre | 1 |
| Pediatric patient months included in Kt/V greater than or equal to 1.7 | 8 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Julia And Israel Waldbaum Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 208 |
| Hypercalcemia patient months | 2006 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 217 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 26 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 145 |
| Patient months included in arterial venous fistula and catheter summaries | 1040 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 78 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
News Archive
University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
StemCells, Inc. announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan.
Infinity Pharmaceuticals, Inc. today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small molecule that targets the Hedgehog pathway.
A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
› Verified 2 days ago